1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sichuan Huiyu Pharmaceutical Co. Ltd. Class A

Sichuan Huiyu Pharmaceutical Co. Ltd. Class A

SSSE:688553
11.01
CNY
+0.31
(+2.90%)
6.65BMarket Cap
Oct 31Next Earn
Sichuan Huiyu Pharmaceutical Co. Ltd. Class A
SSE:688553
(Shanghai Stock Exchange)

Recent

price

11.01

P/E

ratio

- -

div

yld

1.38%

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.03
0.09
1.13
2.55
3.32
2.39
1.48
1.75
1.62
- -
Revenue per Share
-0.16
-0.04
0.28
0.64
0.81
0.4
0.22
0.52
-0.04
- -
Basic EPS, GAAP
-0.04
0.17
0.34
0.43
0.02
-0.43
-0.37
0.18
-0.02
- -
Free Cash Flow per Basic Share
0.02
0.08
0.02
- -
- -
0.14
0.16
0.16
0.32
0.15
Dividend per Share
-0.35
-0.28
0.77
1.41
5.68
5.93
6.01
6.35
5.99
5.96
Book Value per Share
-0.39
-0.31
0.74
1.34
5.57
5.83
5.89
6.21
5.79
5.74
Tangible Book Value per Share
533
627
627
535
550
625
627
625
616
632
Basic Weighted Avg Shares
14
54
707
1,364
1,824
1,493
927
1,094
998
- -
Sales/Revenue/Turnover
-351.06
-80.38
30.05
28.7
25.31
10.38
5.19
7.85
5.96
- -
Operating Margin (%)
27
22
18
25
41
53
64
80
91
- -
Depreciation Expense
-85
-22
177
343
446
249
140
325
-25
- -
Net Income, GAAP
- -
- -
11.62
13.78
6.67
- -
- -
9.67
- -
- -
Effective Tax Rate (%)
-605.83
-40.51
25.02
25.17
24.45
16.67
15.08
29.73
-2.5
- -
Profit Margin (%)
-320
-202
173
358
2,741
2,347
1,991
2,208
1,992
1,989
Working Capital
- -
125
- -
7
3
5
2
- -
- -
- -
LT Debt
-185
-151
409
751
3,558
3,718
3,774
3,973
3,747
3,718
Total Equity
- -
- -
67.07
54.24
20.36
- -
- -
7.17
- -
- -
Return on Invested Capital (%)
- -
- -
73.13
56.46
20.59
- -
- -
7.9
- -
- -
Return on Capital (%)
- -
- -
- -
59.19
20.69
6.84
3.73
8.4
-0.65
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
603
691
707
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
627
627
626
Market Capitalization
7,536
7,074
6,653

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,173
3,300
3,379
Cash, Cash Equivalents & STI
2,682
2,762
2,779
Accounts Receivable, Net
92
84
139
Inventories
264
281
306
Total Current Liabilities
1,181
1,265
1,391
Payables & Accruals
- -
- -
- -
ST Debt
603
691
707
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
75.82%
-5.7%
Free Cash Flow
- -
-508.75%
-112.86%
Net Income, GAAP
- -
-6.61%
-107.67%
Sales/Revenue/Turnover
- -
-2.62%
-8.79%
Total Cash Common Dividend
- -
2,602%
102.85%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
243
290
320
243
1,094
2025
239
214
- -
256
998
2026
269
283
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.03
0.26
0.16
0.52
2025
-0.04
-0.09
- -
0.04
-0.04
2026
0.03
0.06
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.14
- -
0.01
0.16
2025
- -
0.31
- -
0.01
0.32
2026
- -
0.14
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) researches, develops, produces, and sells anti-tumor injection drugs and other pharmaceutical products, with a primary focus on oncology therapeutics including innovative cancer drugs and high-quality generic injections; its core portfolio encompasses injectable amifostine, calcium levofolinate injection, cyclophosphamide for injection, decitabine injection, cladribine injection, methotrexate injections, gemcitabine hydrochloride for injection, fluorouracil injection, fludarabine injection, epirubicin hydrochloride injection, bortezomib hydrochloride injection, irinotecan injection, bendamustine hydrochloride for injection, oxaliplatin injection, paclitaxel injection, azacitidine for injection, docetaxel injection, pemetrexed disodium for injection, polymyxin B sulfate for injection, teicoplanin for injection, and meropenem sodium chloride injections, among others. The company also engages in active pharmaceutical ingredients (API) production, contract development and manufacturing organization (CDMO/CMO) services, and advanced formulation technologies such as long-acting implants, microspheres, liposomes, and albumin-bound drugs. Founded in 2010 and headquartered in Neijiang, Sichuan Province, China, with an R&D center in Chengdu's Tianfu International Biotech City and subsidiaries in the United States, United Kingdom, and Ireland, Sichuan Huiyu operates through hospital, retail, online, and distributor channels in China and internationally, serving domestic and global markets with facilities certified under China NMPA, EU EDQM, UK MHRA, and U.S. FDA GMP standards. In recent developments, its UK subsidiary Seacross Pharmaceuticals secured marketing authorizations for five new drugs and EU MIA product release qualifications; the company entered a strategic distribution partnership in early 2025 with Lakeside Holding Limited's Hupan Pharmaceutical subsidiary to expand oncology and immunotherapy drug distribution globally; additionally, it advanced multiple R&D and production bases, achieved milestones like pemetrexed disodium as China's first injection to pass consistency evaluation, and earned recognitions including National Technological Innovation Demonstration Enterprise in 2023 and Top 100 Chinese Chemical Pharmaceutical Enterprises.